Q2/2025 6/30/2025 EPS -0.870 ZacksConsensus -0.730 ActVsEst (0.140) - Miss
MoonLake Immunotherapeutics - Class A Ordinary Shares (MLTX)
Company Research
Source: Wall Street Horizon
Impact Snapshot
Event Time:
MLTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MLTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MLTX alerts
High impacting MoonLake Immunotherapeutics - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MLTX
News
- MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "mixed" rating to a "sell" rating.MarketBeat
- MoonLake Immunotherapeutics (NASDAQ:MLTX) was given a new $24.00 price target on by analysts at UBS Group AG.MarketBeat
- MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock, up previously from $26.00.MarketBeat
- MoonLake Immunotherapeutics (NASDAQ:MLTX) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating.MarketBeat
- MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
MLTX
Earnings
- 11/5/25 - Miss
MLTX
Sec Filings
- 1/9/26 - Form 4
- 1/9/26 - Form 4
- 1/9/26 - Form 4
- MLTX's page on the SEC website